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1. Introduction and literature review 
 
1.1. Introduction 
 
According to the European Commission’s 2018 Industrial R&D Scoreboard, EU companies have 
increased their investment in research and development (R&D) every year since 20091. A Simple 
explanation is that investing in R&D is usually the most important thing when it comes to companies’ 
long-term competitiveness. Especially, companies in competitive industries, for example in the 
automobile, health and ICT sector, often compete against their rivals on different R&D projects. 
These innovation races are important for every company since the first one to complete the R&D 
project will often force other firms to stop or abandon similar projects. Since the firm value is based 
on expected cash flows and they are affected by R&D projects, losing an innovation race and 
abandoning the project substantially decreases firm value.  
 
In this paper, I study the joint effect between R&D investment and market competition on stock 
returns in developed European countries. I establish two hypotheses that are based on partial 
equilibrium model developed by Berk, Green, and Naik (2004): H1: Positive relation between R&D 
investment level and stock return is stronger in competitive industries, and H2: Positive relation 
between competition level and stock return is stronger among R&D-intensive companies. These 
hypotheses result in a joint effect that high competition and high investments in R&D have a strong 
positive interaction effect on the share price. In the model, the R&D project consists of different 
sequential stages that a company has to go through in order to complete the project. After the firm 
has completed all the needed stages, it receives a steam of cash flows from the invention. At any stage 
before completing the project, the manager has to make an investment decision, which maximizes the 
firm’s future cash flows and therefore its market value. Prior to completing the project, the company 
knows its future cash flows from the project. If the firm decides to advance to the next stage, it will 
cause an investment cost for the company.  
 
Competition risk is denoted by the obsolescence rate in the model, and it indicates the probability that 
the future cash flows are extinguished over the next stage. A higher rate expresses the higher 
probability that the cash flows will become zero and therefore lowers the benefits of R&D 
investments. This rate is usually higher for firms operating in competitive industries because they 
 
1 https://ec.europa.eu/jrc/en/news/2018-industrial-rd-scoreboard 
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often find themselves competing in innovation races to develop new technology and products. The 
winner of the race takes the market share to itself and other firms have to suspend or abandon their 
projects, which leads to zero future cash flows. Companies also have a certain threshold for the future 
cash flow and if this cash flow is not exceeded, the firm will suspend the project. A higher threshold 
means that the project is riskier since the probability that the project is abandoned or suspended 
increases if an adverse shock to the potential cash flow occurs. High R&D investment requirement 
raises the threshold since it lowers the value of the option to continue the project to the next stage. 
Thus, higher R&D requirement demands higher risk premium, and therefore firms that invest a lot in 
R&D have higher expected returns. To conclude, the model suggests that firms, which invest 
aggressively in R&D in competitive industries, have higher expected returns. 
 
I use the double-sorting approach to test empirically the model’s predictions and I show a positive 
joint effect between industry competition level and R&D-intensity. My findings show that positive 
relation between R&D level and stock returns exist in both, competitive and concentrated industries, 
but the relation is much stronger among competitive industries. The raw returns and abnormal returns 
in the asset-pricing models gradually increase when R&D-intensity increases. This is shown by all 
three asset-pricing models that I use: Fama-French three-factor model, Carhart four-factor model, and 
Fama-French five-factor model (see Fama and French 1992, 2015, and Carhart 1997). The pattern is 
shown when using all the firms in the sample and also when small stocks are excluded. For example, 
when microcap stocks are excluded, the monthly equally weighted three-factor alphas on high, 
medium and low R&D-intensity portfolios in high competition industries are 0.35%, -0.06% and -
0.30%, respectively, with t-statistics of 2.08, 0.44 and 2.02. The return for the high-minus-low 
portfolio is 0.65% per month and is statistically significant at 1% level. In contrast, the three-factor 
alphas on high, medium and low R&D-intensive portfolios in low competition industries are 0.04%, 
-0.07% and -0.33%, with t-statistics of 0.28, 0.58 and 2.72, respectively. The return for the high-
minus-low portfolio is 0.37% per month and is statistically significant at 5% level. 
 
My findings also show that the positive relation between competition level and stock return exists 
only between R&D-intensive firms. The raw return and abnormal returns gradually increase among 
high R&D-intensity portfolios but this effect is not reported on the low R&D-intensity group. These 
findings can be seen on all three asset-pricing models when using either all firms or excluding 
microcap stocks. For example, when excluding microcap firms from the sample, the Fama-French 
three-factor model reports abnormal monthly returns among low R&D-intensity group on high, 
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medium and low competition portfolios of -0.30%, -0.29% and -0.33%, respectively. T-statistics for 
the results are 2.02, 1.89 and 2.72. The return on the high-minus-low competition portfolio is 0.03% 
and insignificant. In contrast, the corresponding results for the high R&D-intensity group are 0.35%, 
0.12% and 0.04% with t-statistics of 2.08, 0.83 and 0.28, respectively. The return on the high-minus-
low competition portfolio is 0.31% and significant at 5% level. 
 
The results show a strong relation to the existing literature. My findings show that there is a positive 
relation between R&D investments and stock returns. For example, Chan, Lakonishok, and 
Sougiannis (2001) found this relation in their paper. In addition, my findings suggest that firms in 
competitive industries earn higher returns than those in concentrated industries. This effect is studied 
by Hou and Robinson (2002), who found the same results. Gu (2016) found that among low 
competition industries, firms that invest aggressively in R&D do not make abnormal returns, but even 
generate negative excess returns. My findings do not follow this last statement. 
 
This paper has two contributes to the literature. First, it shows the relation between R&D intensity 
and stock returns. (see, e.g., Lev and Sougiannis, 1996; Chan, Lakonishok, and Sougiannis, 2001; 
Chambers, Jennings, and Thompson, 2002; Eberhart, Maxwell, and Siddique, 2004; Hsu, 2009; Bena 
and Garlappi, 2011; Li, 2011; Lin, 2012; Hirshleifer, Hsu, and Li, 2013; Cohen, Diether, and Malloy, 
2013). These prior studies show positive premiums among R&D-intensive firms. Second, this paper 
reports the relation between competition and stock returns in Europe. For example, Hou and Robinson 
(2002) find that firms in competitive industries outperform firms that operate in concentrated 
industries by earning higher returns on average. Aguerrevere (2009) reports that the relation between 
competition and stock returns varies along with product market demand. 
 
The rest of the paper is organized as follows. Section 1.2 provides a literature review of R&D 
investments and stock returns. Section 2 describes the developing of hypotheses from the model. 
Section 3 provides the data and methodology. Section 4 reports the results. Section 5 shows 
robustness checks. Section 6 concludes.   
 
1.2. Literature review 
 
The relation between R&D expenditures and stock return has interested researchers for many decades. 
The evidence indicates that investors see R&D expenditures as investments that are going to produce 
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benefits in the future and investors value these benefits when pricing stocks. In several papers, 
researchers have found abnormal returns for companies, which invest a lot in R&D. The positive 
relation between R&D intensity and abnormal returns is reported by Lev and Sougiannis (1996) and  
Chan, Lakonishok and Sougiannis (2001) who found that firms with high R&D value relative to 
market equity have an average excess return over the following three years is over 6% per year. Also, 
Lev, Sarath, and Sougiannis (2000) and Penman and Zhang (2002) report a positive relation between 
recent changes in R&D expenditures and stock returns. Firms that increase their R&D investments 
have significant abnormal returns. Finally, firms that announce new R&D investments, tend to have 
excess returns on their share during the announcement-period. For example, Chan, Martin, and 
Kensinger (1990), found that in the U.S. between 1979 and 1985, firms that announced plans to 
increase their research and development investments had statistically significant positive abnormal 
returns during the next two days after the announcement. 
 
What makes intensive R&D firms generate abnormal returns then? This topic has been studied by 
Chambers, Jennings, and Thompson (2002) who tested two different reasons for excess returns. The 
first explanation could be that the stocks are mispriced because of the conservative accounting for 
R&D expenditures. Firms inform their R&D costs with caution that will make future earnings lower 
and that way affects the share price. The second reason could be that conventional risk controls do 
not fully capture the riskiness of high R&D companies, which is causing measured abnormal returns 
for these companies to be biased. Chambers at al. came to conclusion that positive relation between 
R&D expenditure levels and stock returns is more likely due to a failure in risk controls than from 
mispricing. However, their results do not rule out the possibility that abnormal returns are due to 
mispricing when studying the relation between R&D expenditure changes and stock returns. 
 
R&D investments are not valuable only for companies that are doing well, but it can be significantly 
important for firms that are facing challenging times. Chan, Martin, and Kensinger (1990) found out 
that R&D announcements give positive returns also for firms that experience earnings decrease at the 
same time. In addition, Chan, Lakonishok, and Sougiannis (2002) found that firms that invest heavily 
in R&D but have poor past performance and cost-cutting pressures, tend to avoid the decrease in 
stock price. Investing in R&D informs managers’ optimistic views about the company’s future 
prospects even in bad situations. This highlights the fact that investors do not only value strategic 
investments that affect companies’ short-term earnings but look beyond it when valuing a company’s 
stock.  
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There have been findings of how R&D expenditures affect the stock price in different industries and 
market types. High investments do not always guarantee positive and abnormal returns, but the 
industry type is also a key factor. Gu (2016) study the R&D effect on different levels of market 
competition. His results from the U.S. stock market show that R&D-intensive firms only generate 
excess returns in competitive markets. R&D-intensive firms in concentrated industries do not 
generate excess returns and they even have negative returns. According to Chan, Martin, and 
Kensinger (1990), an increase in R&D spending is not rational in industries that are technologically 
mature. In high-technology industries, an increase in R&D yields significant positive abnormal 
returns but in low-technology industries, it generates significant negative returns.  
 
2. Hypothesis 
 
I follow the partial equilibrium model created by Berk, Green, and Naik (2004) to study the joint 
effect between industry competition and R&D investments on stock returns. In this model, the 
company operates in continuous time and advances through the R&D project in sequential stages. 
After the firm successfully completes N amount of separate stages and completes the project, it 
receives a stream of cash flows. At any time before the final stage and completing the project, the 
manager of the firm has to make an investment decision to maximize the firm’s future cash flows and 
its market value. If the manager decides to continue the project from stage n to n + 1, it will cause an 
investment cost for the company.  
 
Competition risk is denoted by the obsolescence rate, which indicates the probability that the future 
cash flows are extinguished over the next stage. The competition risk is idiosyncratic and therefore 
does not require a risk premium for itself. Nonetheless, a high obsolescence rate indicates a high 
probability that future cash flows will become zero. Therefore, the high obsolescence rate lowers the 
benefits of R&D expenditures and consequently the value of the option to continue the project to the 
next stage. In the end, the obsolescence rate indirectly affects the firm’s systematic risk because it 
affects the company’s decision whether they continue with the project or suspend it.  
 
Companies that operate in competitive markets, often find themselves competing against their rivals 
in innovation races to develop new technology or product. The winner of this race often takes the 
market share to itself. Other firms in the industry have to then either suspend or abandon their projects 
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and therefore face zero future cash flows. When compared to concentrated industries, firms can 
launch their innovation projects with less fear when of obsolescence since there are fewer 
competitors. Therefore, the obsolescence rate is often higher for firms operating in competitive 
industries. 
 
Hypothesis 1: Positive relation between R&D investment level and stock return is stronger in 
competitive industries 
 
The firm has to make an investment decision at any stage before completing the project. Firms also 
have certain thresholds for their future cash flows and if this cash flow target is not exceeded, the 
firm will suspend its R&D project. A higher threshold means that the project is riskier since the 
probability that the project is abandoned or suspended increases if an adverse shock to the potential 
cash flow occurs. Thus, the company’s investment decision and its value are more prone to the 
systematic risk that the future cash flow carries. A higher R&D investment requirement raises the 
future cash flow threshold since it tends to lower the value of the option to continue the project. In 
consequence, a higher requirement for R&D investments results in higher risk premiums, and 
therefore, companies that invest aggressively in R&D tend to have higher expected returns. To 
conclude, the obsolescence rate is higher in competitive industries and for those companies that invest 
heavily in R&D. If a firm operates in a competitive industry and has high R&D-intensity, its 
obsolescence rate is even higher and therefore increases the future cash flow threshold. The first 
hypothesis is based on this argument.  
 
Hypothesis 2: Positive relation between competition level and stock return is stronger among R&D-
intensive companies 
 
As stated on the previous hypothesis, a high obsolescence rate results in a higher probability that 
future cash flows will be extinguished and therefore decreases the potential benefits of continuing 
with the R&D project. Thus, companies in industries that have higher obsolescence rates have to pass 
higher future cash flow thresholds if they want to continue with the project. The outcome is that these 
companies have higher risk premiums. In other words, companies in more competitive industries have 
higher expected returns on their stock. As in hypothesis 1, the firms with high R&D investments also 
have higher expected returns. This joint effect raises the future cash flow threshold. The second 
hypothesis is based on this argument.  
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3. Data and methodology 
 
3.1. Data 
 
The data includes listed and delisted stocks from developed European countries. The list of countries 
is based on K. French’s data library2 (see table 1). Companies’ monthly stock returns from 1991 to 
2019 and yearly accounting information from 1989 to 2017 are collected from Thompson Reuters 
Datastream. I follow Hou and Robinson (2006), and divide firms into different industries according 
to their Standard Industrial Classification (SIC) code from Datastream. Firms with SIC codes between 
6000 and 6799 (financial firms) are excluded from the dataset due to the regulation in these industries. 
I use three-digit SIC codes since four-digit industry classification results in statistically unreliable 
portfolios, but on the other hand, two-digit classification groups different businesses together. 
Original sample included 5848 companies and after excluding financial firms and firms without SIC 
code, the final sample size is 4350 companies.  
 
I follow Fama and French (1992) to make sure accounting information is already included in firms’ 
stock returns. I match accounting information for all fiscal year-ends in calendar year t – 1 with 
Datastream stock returns from July of year t to June of year t + 1. Therefore, a minimum gap of six 
months exists between the stock return and fiscal year-end, which ensures enough time for accounting 
information to be included in stock returns. However, the time gap differs between firms’ accounting 
information and matching stock return due to different fiscal year-ends. 
 
In this paper, firms’ R&D intensity is measured by R&D investment divided by market equity 
(RD/ME) following to Hou, Xue, and Zhang (2015). They show that only RD/ME can forecast returns 
and other measures of R&D intensity, for example, RD/Sales, fail to generate significant returns on 
US stocks. Their findings highlight the need to understand this R&D-to-market anomaly better. Thus, 
measuring R&D intensity in this paper is more meaningful by using RD/ME. Firms without R&D 
data are excluded from R&D intensity calculations. The final sample size includes 1957 companies.  
 
 
 
 
 
2 http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/Data_Library/f-f_5developed.html 
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(1) 
Table 1. Following K. French’s data library, the table shows the list of countries that are included in the sample. The 
original sample includes all listed and delisted stocks from 1989 to 2019. The next column shows all the companies that 
have the Standard Industrial Classification (SIC) code and are not financial firms. The final sample includes all the 
firms that have available R&D data. 
 
 
Competitiveness in each industry is measured by the Herfindahl-Hirschman Index (HHI), which is 
used in several papers (see eg. Cetorelli and Strahan (2006) Giroud and Mueller (2011) and Sheen 
(2014)). The Index gives values for each industry between zero and 10,000, and smaller value means 
more competition. The HHI is calculated by squaring the market share of each individual firm 
competing in the industry and then summing all the results together: 
 
𝐻𝐻𝐼𝑗𝑡 = ∑ 𝑠𝑖𝑗𝑡
2
𝑁𝑗
𝑖=1
     
 
where HHIjt is the Herfindahl Index of industry j in year t, Nj is the number of firms in industry j in 
year t, and sijt is the market share of firm i in industry j in year t.  The market share for each company 
is calculated by using the firm’s net sales divided by the total sales of the whole industry. Companies’ 
asset or equity values could be used instead of net sales. Following Gu (2016), these values produce 
similar results. Firms with missing sales value are excluded from the sample to calculate the 
Herfindahl Index for each industry. The index is calculated each year and I use the average value of 
past two years to prevent possible data errors. 
 
Coutry of exchange Original sample
Firms with SIC codes 6000-
6799 or  without SIC code 
excluded
Final sample: Firms with 
available R&D data 
Austria 62 46 31
Belgium 134 89 48
Denmark 150 105 49
Finland 150 130 81
France 730 621 292
Germany 766 578 322
Greece 176 155 84
Ireland 29 22 12
Italy 316 246 85
Netherlands 113 84 45
Norway 237 181 67
Portugal 52 45 10
Spain 210 138 41
Sweden 665 578 178
Switzerland 244 161 104
United Kingdom 1814 1171 508
Total 5848 4350 1957
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Table 2. Values of the Herfindahl-Hirschman Index (HHI) for every year. 
 
 
3.2. Methodology 
 
In this subsection, I demonstrate how the portfolios are built. I use a double-sorting approach where 
in June of each year t, all stocks are divided into three different classes based on the breakpoints for 
the bottom 30% (low HHI), middle 40% (medium HHI), and top 30% (high HHI) according to their 
Herfindahl Index in year t - 1. Then, for all three classes, companies with non-missing R&D value 
are individually divided into three groups based on the breakpoints for the bottom 30%, middle 40%, 
and top 30% of RD/ME values from the year t – 13. From these, I form nine different portfolios 
regarding to the R&D intensity and degree of competition. 
 
First, I construct portfolios by using all companies and their equally weighted returns to show my 
empirical findings. This might create unreliable results because of small size companies. Due to their 
 
3 Following Gu (2016), These breakpoints could be sorted by quintile breakpoints that give similar results. 
Year Min Median Max
Top 30% 
breakpoint 
Bottom 30% 
breakpoint
Most competitive 
industry
1990 1495.4 5385.2 10000 3033.8 5501.4 Grocery stores
1991 1529.2 5291.1 10000 2867.5 5339.2 Grocery stores
1992 1295.4 5307.7 10000 2722.1 5189.0 Motor vehicles
1993 1534.9 5349.3 10000 2657.4 5060.1 Electric services
1994 1396.1 5337.6 10000 2467.9 5002.1 Electric services
1995 1183.5 5323.1 10000 2425.3 5000.1 Computer services
1996 1035.2 5351.3 10000 2068.3 4955.4 Computer services
1997 929.7 5244.2 10000 1725.0 4891.2 Computer services
1998 852.5 5271.6 10000 1662.3 4632.8 Computer services
1999 762.3 5309.5 10000 1511.7 4662.6 Computer services
2000 701.4 5442.6 10000 1520.4 3834.2 Computer services
2001 703.4 5264.4 10000 1455.1 3700.6 Computer services
2002 648.9 5241.8 10000 1399.4 3777.0 Computer services
2003 585.7 5295.2 10000 1318.7 3541.8 Computer services
2004 568.3 5156.6 10000 1265.5 3505.7 Computer services
2005 571.9 5095.9 10000 1279.9 3512.4 Computer services
2006 550.1 5139.7 10000 1335.0 3393.6 Computer services
2007 518.6 5084.4 10000 1237.1 3380.5 Computer services
2008 499.1 5002.9 10000 1204.2 3336.4 Computer services
2009 478.6 4973.2 10000 1165.2 3315.6 Computer services
2010 475.4 4846.5 10000 1181.8 3268.6 Computer services
2011 494.0 4866.3 10000 1177.6 3280.9 Computer services
2012 512.7 4797.5 10000 1156.0 3105.4 Computer services
2013 512.5 4841.6 10000 1140.6 2937.8 Computer services
2014 497.0 4730.1 10000 1131.0 2753.9 Computer services
2015 494.8 4864.6 10000 1112.6 2561.5 Computer services
2016 498.1 4861.6 10000 1098.4 2482.3 Computer services
2017 486.9 4897.1 10000 1097.2 2430.7 Computer services
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small size, microcap firms usually have rather high RD/ME value when compared to larger firms and 
therefore they are assigned to R&D-intensive groups. This could affect the interpretation of the 
returns on the R&D-intensive portfolios. To minimize the effect of the microcap companies, I follow 
Hou, Xue, and Zhang (2015) to calculate my findings. For the second part, I exclude the smallest 
20%, based on the market value, each year and then use equally weighted returns. I call these two 
different construction methods “all stocks” and “small-cap stocks excluded”. 
 
The nine portfolios for both, all stocks and small-cap stocks excluded, are calculated from July of 
year t to June of next year, t – 1. Portfolios are rebalanced every June. To calculate returns, I use the 
Fama-French three-factor model, Carhart four-factor model, and Fama-French five-factor model. 
Model specifications that I estimate: 
 
𝑅𝑡 = 𝛼 + 𝛽1 ∗ 𝑀𝐾𝑇𝑡 + 𝛽2 ∗ 𝑆𝑀𝐵𝑡 + 𝛽3 ∗ 𝐻𝑀𝐿𝑡 + 𝜀𝑡  (2) 
 
𝑅𝑡 = 𝛼 + 𝛽1 ∗ 𝑀𝐾𝑇𝑡 + 𝛽2 ∗ 𝑆𝑀𝐵𝑡 + 𝛽3 ∗ 𝐻𝑀𝐿𝑡 + 𝛽4 ∗ 𝑈𝑀𝐷𝑡 + 𝜀𝑡  (3) 
 
𝑅𝑡 = 𝛼 + 𝛽1 ∗ 𝑀𝐾𝑇𝑡 + 𝛽2 ∗ 𝑆𝑀𝐵𝑡 + 𝛽3 ∗ 𝐻𝑀𝐿𝑡 + 𝛽4 ∗ 𝑅𝑀𝑊𝑡 + 𝛽5 ∗ 𝐶𝑀𝐴𝑡 + 𝜀𝑡 (4) 
 
where Rt is the portfolio’s monthly excess return and MKTt is the value-weighted market return minus 
the risk-free rate in month t. In the Fama-French three-factor model, SMBt, and HMLt are the month 
t size factor and book-to-market factor. In the Carhart four-factor model, UMDt is the month t 
momentum factor. In the Fama-French five-factor model, RMWt, and CMAt are the month t 
profitability factor and investment factor. All the factors are downloaded from the Kenneth R. 
French’s data library4. 
 
4. Results 
 
In this part, I investigate and show my empirical findings of the joint effect between R&D investment 
and market competition. 
 
 
4 http://mba.tuck.dartmouth.edu/pages/faculty/ken.french/data_library.html#International  
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4.1. Relation between R&D-intensity and stock return in competitive and 
concentrated industries 
 
Table 3 shows monthly raw return and abnormal return (i.e., alpha in the pricing model) for each 
portfolio in concentrated (top 30% of the HHI) and competitive (bottom 30% of the HHI) industries. 
In Panel A, I use all the stock and their equal-weighted return. In Panel B, I exclude small-cap firms 
that are below 20% based on the market value and then use all remaining stocks and their equal-
weighted return.  
 
Table 3. Research and development investments -return in competitive and concentrated industries. This table shows 
each portfolio’s monthly raw return and abnormal return (α, in per cents). Stocks that are used, are exchanged in developed 
European countries. The list of countries is based on Kenneth R. French’s data library. Portfolios are sorted on industry 
competition and R&D intensity. Industry competition is measured by the Herfindahl-Hirschman Index (HHI) (See section 
3 for definition). Each firm’s industry is determined by the three-digit Standard Industrial Classification (SIC) code. R&D 
intensity is calculated by dividing R&D investment with market equity (RD/ME). All stocks are allocated into three 
groups based on their HHI-values in year t - 1, using breakpoints for the top 30% (low HHI), middle 40% (medium HHI) 
and bottom 30% (high HHI). Then, in all groups, firms are individually divided into three subgroups based on their 
RD/ME value in year t – 1 and using breakpoints for top 30%, middle 40% and bottom 30%. Monthly returns for formed 
portfolios are then calculated from July year t to June year t + 1 and portfolios are rebalanced after every June. The 
premium column shows the difference between H-L portfolios of Low HHI and High HHI groups. Monthly abnormal 
returns of portfolios are computed by time-series regression of excess returns on factors in Fama and French (1992, 2015) 
three- and five-factor models and in Carhart (1997) four-factor model. In Panel A, I use all the stocks and their equally 
weighted returns. In Panel B, I exclude small-cap stocks, which are below 20% based on market value and then use all 
remaining stocks and their equal-weighted return. The sample period is from July 1991 to June 2019. The t-statistics are 
noted below monthly abnormal returns in parenthesis. The significance levels for 1%, 5% and 10% are shown by ***, ** 
and *, respectively. 
 
 
R&D H R&D M R&D L H - L R&D H R&D M R&D L H - L Premium
1.31*** 0.78*** 0.65** 0.66*** 1.51*** 0.91*** 0.53* 0.98*** 0.32
(3.99) (2.64) (2.28) (3.45) (4.42) (2.79) (1.67) (4.92) (1.40)
0.44*** -0.05 -0.14 0.58*** 0.63*** 0.09 -0.22 0.95*** 0.27
(2.72) (0.43) (1.05) (3.03) (3.65) (0.65) (1.50) (4.47) (1.22)
0.60*** 0.11 0.08 0.52** 0.72*** 0.25* 0.04 0.68*** 0.16
(3.61) (0.92) (0.59) (2.57) (3.99) (1.68) (0.28) (3.42) (0.68)
0.50*** -0.13 -0.08 0.58*** 0.84*** 0.35** -0.06 0.90*** 0.31
(2.90) (1.08) (0.53) (2.82) (4.58) (2.28) (0.35) (4.36) (1.32)
0.97*** 0.77*** 0.47* 0.50*** 1.26*** 0.77** 0.44 0.82*** 0.32
(2.87) (2.59) (1.66) (3.01) (3.65) (2.33) (1.39) (4.09) (1.59)
0.04 -0.07 -0.33*** 0.37** 0.35** -0.06 -0.30** 0.65*** 0.28
(0.28) (0.58) (2.72) (2.33) (2.08) (0.44) (2.02) (3.41) (1.42)
0.26* 0.07 -0.15 0.41** 0.50*** 0.16 -0.04 0.54*** 0.12
(1.80) (0.61) (1.22) (2.46) (2.86) (1.08) (0.25) (2.67) (0.60)
0.12 -0.14 -0.36*** 0.48*** 0.53*** 0.20 -0.12 0.65*** 0.17
(0.76) (1.21) (2.73) (2.78) (2.96) (1.32) (0.73) (3.13) (0.79)
Carhart four-factor
Fama-French five-factor 
Panel A: All stocks
Panel B: Small-cap stocks excluded
Fama-French five-factor 
Low competition (High HHI) High competition (Low HHI)
Raw return
Fama-French three-factor 
Raw return
Fama-French three-factor 
Carhart four-factor
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Panel A includes the small-cap stocks which are often placed in high-intensity R&D portfolios in 
both competitive and concentrated industries. The returns on these two portfolios according to all 
three asset-pricing models are positive and highly significant which do not support the prior studies 
that in low competition group R&D-intensive firms do not generate abnormal returns. Panel A still 
supports the hypothesis that positive R&D-return relation is stronger in competitive industries. 
 
As regards to my findings, first, the raw return on the high-minus-low portfolio is highly significant 
in competitive and as well in concentrated industries. This is shown in both panels and the monthly 
return difference between the two groups is highlighted in the premium column in the table. In both 
panels, the raw returns gradually increase when the level of R&D increases. From the panels, we can 
see that in competitive industries the premium for the high-minus-low portfolio is larger and more 
significant. In Panel A, the monthly raw return for the high-minus-low portfolio in competitive 
industries is 0.98% with a t-statistic of 4.92. The corresponding values in concentrated industries are 
0.66% per month and the t-statistic of 3.45. In the Panel B, the monthly raw return for the high-minus-
low portfolio in competitive industries is 0.82% with 4.09 t-statistic. In contrast, the return in 
concentered industries is 0.5% with 3.01 t-statistic.  
 
Second, as shown in the Panels, abnormal returns increase gradually in low competition as well as in 
high competition industries. For instance, in Panel B, the Fama-French three-factor model for 
competitive industries for high, medium and low R&D-portfolios shows monthly alphas of 0.35%, -
0.06% and -0.30% with t-statistics 2.08, 0.44 and 2.02, respectively. The high-minus-low alpha is 
0.65%, with a t-statistic of 3.41, which returns 7.80% annually. For concentrated industries, these 
values are 0.04%, -0.07% and -0.33% with t-statistics 0.28, 0.58 and 2.72, respectively. The high-
minus-low alpha is 0.37%, with a t-statistic of 2.33, which translates to a yearly return of 4.44%. This 
is in line with previous cites that R&D investments are one of the most important drivers that affect 
the firm’s stock return and companies that invest more will generate higher returns. However, only 
in competitive industries, firms that invest aggressively in R&D can generate high significant 
abnormal returns. This can be seen from all three asset pricing models that return monthly alphas of 
0.35%, 0.50% and 0.53% with t-statistics of 2.08, 2.86 and 2.96, respectively. In contrast, the 
corresponding estimates in concentrated industries are 0.04%, 0.26% and 0.12% with t-statistics of 
0.28, 1.80 and 0.76, respectively. Portfolios that include companies with a low contribution in R&D 
return negative alphas in both, competitive and concentrated industries. The negative return is higher 
in concentrated industries. Fama-French three-factor, Carhart four-factor and Fama-French five-
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factor monthly alphas for low R&D portfolio in concentrated industries are -0.33%, -0.15% and -
0.36% with t-statistics of 2.72, 1.22 and 2.73, respectively. The corresponding values in competitive 
industries are -0.30%, -0.04% and -0.12% with t-statistics of 2.02, 0.25 and 0.73, respectively.  
 
In Panel A for R&D-intensive portfolio in concentrated industries generates significant monthly 
abnormal returns. This is not in line with prior studies and not seen in Panel B, therefore it can be due 
to small-cap firms. Nonetheless, when analyzing both panels, the monthly returns and the t-statistics 
for the high-minus-low portfolio are significant at the 1% level for all three asset-pricing models in 
competitive industries. Compared to concentrated industries, only the Fama-French five-factor model 
in Panel B gives a t-statistic at 1% significance level and two other models report significance levels 
at 5%.  
 
To conclude, the results in Table 3 support the hypothesis that the positive relation between R&D 
investments and stock return is stronger in competitive industries than in concentrated industries. The 
return premium decreases for R&D-intensive firms that operate in concentrated industries. This is 
shown by high-minus-low portfolios. The results suggest that earlier cites about positive relation 
between R&D investments and stock returns are a combination of firms operating in industries with 
different degrees of competition. This positive joint relation is mainly driven by companies in 
competitive industries. In addition, aggressive investing in R&D usually affects a firm’s risk profile 
and its expected returns. The results suggest that these effects can be very different between firms 
that have the same degree of R&D intensity but are operating in industries with different levels of 
competitiveness. For example, in Panel B, firms that aggressively invest in R&D are able to generate 
abnormal returns only in competitive industries Thus, the level of competition explains a significant 
portion of the positive relation between R&D and returns. Finally, the findings suggest that no matter 
the level of competitiveness, firms have to invest in R&D, or they will likely generate negative 
abnormal returns.  
 
4.2. Relation between competition level and stock return among R&D-intensive 
firms 
 
In this section, I test the second hypothesis that the positive relation between competition level and 
stock return is stronger among R&D-intensive firms than with firms that invest only a little on R&D. 
In Table 4, portfolios are grouped into two different groups based on the intensiveness of their R&D 
expenditures. Low R&D intensity group includes the firms, which are in the bottom 30%, and high 
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R&D intensity group contains companies that are in the top 30% according to their RD/ME-value. In 
Panel A, I use all the stock and their equally weighted return. In Panel B, I exclude small-cap firms 
that are below 20% based on market value and then use all remaining stocks and their equally 
weighted return.  
 
Table 4. Research and development investments -return in competitive and concentrated industries. This table shows 
each portfolio’s monthly raw return and abnormal return (α, in per cents). Stocks that are used, are exchanged in developed 
European countries. The list of countries is based on Kenneth R. French’s data library. Portfolios are sorted on industry 
competition and R&D intensity. Industry competition is measured by the Herfindahl-Hirschman Index (HHI) (See section 
3 for definition). Each firm’s industry is determined by the three-digit Standard Industrial Classification (SIC) code. R&D 
intensity is calculated by dividing R&D investment with market equity (RD/ME). All stocks are allocated into three 
groups based on their HHI-values in year t - 1, using breakpoints for the top 30% (low HHI), middle 40% (medium HHI) 
and bottom 30% (high HHI). Then, in all groups, firms are individually divided into three subgroups based on their 
RD/ME value in year t – 1 and using breakpoints for top 30%, middle 40% and bottom 30%. Monthly returns for formed 
portfolios are then calculated from July year t to June year t + 1 and portfolios are rebalanced after every June. The 
premium column shows the difference between L-H portfolios of High R&D and low R&D groups. Monthly abnormal 
returns of portfolios are computed by time-series regression of excess returns on factors in Fama and French (1992, 2015) 
three- and five-factor models and in Carhart (1997) four-factor model. In Panel A, I use all the stocks and their equally 
weighted returns. In Panel B, I exclude small-cap stocks, which are below 20% based on market value and then use all 
remaining stocks and their equal-weighted return. The sample period is from July 1991 to June 2019. The t-statistics are 
noted below monthly abnormal returns in parenthesis. The significance levels for 1%, 5% and 10% are shown by ***, ** 
and *, respectively. 
 
 
First, when analyzing raw returns in Panel B, the results show that the monthly return on the high-
minus-low competition portfolio is positive and insignificant in the low R&D-intensive group. In 
contrast, the return for the high R&D-intensive group is positive and significant. The monthly return 
on the high-minus-low competition portfolio for a low R&D-intensity group is -0.03% with a t-
statistic of 0.21. The comparable result for the high R&D-intensive group is monthly return of 0.29% 
HHI L HHI M HHI H L - H HHI L HHI M HHI H L - H Premium
0.53* 0.53* 0.65** -0.12 1.51*** 1.34*** 1.31*** 0.20 0.32
(1.67) (1.68) (2.28) (0.68) (4.42) (3.94) (3.99) (1.22) (1.40)
-0.22 -0.31** -0.14 -0.08 0.63*** 0.46*** 0.44*** 0.19 0.27
(1.50) (2.17) (1.05) (0.51) (3.65) (2.74) (2.72) (1.14) (1.22)
0.04 -0.04 0.08 -0.04 0.72*** 0.64*** 0.60*** 0.12 0.16
(0.28) (0.26) (0.59) (0.24) (3.99) (3.66) (3.61) (0.67) (0.68)
-0.06 -0.21 -0.08 0.02 0.84*** 0.71*** 0.50*** 0.34* 0.31
(0.35) (1.42) (0.53) (0.13) (4.58) (3.95) (2.90) (1.87) (1.32)
0.44 0.57* 0.47* -0.03 1.26*** 1.01*** 0.97*** 0.29** 0.32
(1.39) (1.74) (1.66) (0.21) (3.65) (3.04) (2.87) (2.01) (1.59)
-0.30** -0.29* -0.33*** 0.03 0.35** 0.12 0.04 0.31** 0.28
(2.02) (1.89) (2.72) (0.22) (2.08) (0.83) (0.28) (2.13) (1.42)
-0.04 0.01 -0.15 0.11 0.50*** 0.32** 0.26* 0.24 0.12
(0.25) (0.10) (1.22) (0.75) (2.86) (2.20) (1.80) (1.55) (0.60)
-0.12 -0.20 -0.36*** 0.25 0.53*** 0.31** 0.12 0.41*** 0.17
(0.73) (1.21) (2.73) (1.62) (2.96) (2.00) (0.76) (2.64) (0.79)
Low R&D-intensity High R&D-intensity
Raw return
Panel A: All stocks
Carhart four-factor
Raw return
Fama-French three-factor 
Fama-French five-factor 
Fama-French three-factor 
Carhart four-factor
Fama-French five-factor 
Panel B: Small-cap stocks excluded
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and it is statistically significant at the 5% level. In addition, the similar monthly returns on high-
minus-low competition portfolios are also seen on the Panel A. Even though the estimates are not 
significant, they strengthen the proposition that the level of competitiveness is a major factor among 
R&D-intensive firms. The monthly return difference between the two groups is highlighted in the 
premium column in the table. 
 
Second, Panel B shows that companies in more competitive industries earn higher abnormal returns 
during the sample period, but these excess returns are only seen among R&D-intensive firms. The 
abnormal returns on high-minus-low competition portfolios are small or even negative on for 
companies in the low R&D intensity group. This finding is shown in all three asset pricing models. 
For example, in Panel B and low R&D intensity group, the abnormal monthly returns for high, 
medium and low competition portfolios according to the three-factor model are -0.30%, -0.29% and 
-0.33% with t-statistics of 2.02, 1.89 and 2.72, respectively. The return on the high-minus-low 
competition portfolio is 0.03% with a t-statistic of 0.22. In contrast, the same abnormal monthly 
returns in R&D-intensive group are 0.35%, 0.12% and 0.04% with t-statistics of 2.08, 0.83 and 0.28 
respectively. The return on high-minus-low competition portfolio is 0.31% per month with t-statistic 
of 2.31, which returns in 3.72% yearly premium. The similar results are also shown in both groups 
according to four- and five-factor models. In the low R&D intensity group, the Carhart four-factor 
model does not show any significant abnormal returns and monthly returns are small or negative for 
all three competition portfolios. The monthly return on the high-minus-low competition portfolio is 
0.11% with a t-statistic of 0.75. In contrast, the corresponding returns in high R&D intensity group 
are 0.50%, 0.32% and 0.26% with t-statistics of 2.86, 2.20 and 1.80, respectively. The monthly return 
on the high-minus-low competition portfolio is 0.24% with a t-statistic of 1.55. The high-minus-low 
competition portfolio return according to the five-factor model is 0.25% per month among the low 
R&D-intensity group and 0.41% for the high R&D-intensity group. The t-statistics are 1.62 and 2.64, 
respectively. 
 
Similar results are also reported when including microcap firms in the sample. Panel A shows the 
returns on the high-minus-low competition portfolio in the low R&D intensity group. Three-, four- 
and five-factor models report the monthly returns of -0.08%, -0.04% and 0.02%, respectively. The t-
statistics for the returns are 0.51, 0.24 and 0.13. The corresponding results for high R&D intensity 
group are 0.19%, 0.12% and 0.34% with t-statistics of 1.14, 0.67 and 1.87. In conclusion, the results 
in Table 2 support the second hypothesis that competition premium is stronger among R&D-intensive 
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(5) 
firms. This is mainly shown in high-minus-low competition portfolios, which have higher premiums 
among high R&D intensive group. 
 
5. Robustness test 
 
The results shown in the previous sector show some robustness since I use three different asset-pricing 
models that report similar results between them. In addition, both ways of creating the portfolio give 
compatible end results, even though the panel with all the firms is biased due to its way of including 
small-cap stocks to the high R&D portfolios. The gradual increasing from low R&D-intensity to high 
R&D-intensity is shown on both panels, and the increase is higher among highly competitive 
industries. In this sector, I perform a robustness test with an alternative way of dividing firms into 
competitive and concentrated industries. In the last paragraph, I also report the results from my other 
findings and use previous literature from this topic to show the robustness of my results.  
 
To perform a robustness test, I use the concentration ratio instead of the Herfindahl-Hirschman Index. 
The ratio has been used by many researchers for a long time. For example, Bain (1951) as well as 
Hall and Tideman (1967), use it in their papers. The concentration ratio (CR) is known to be the 
simplest way to calculate the concentration of the industry. The CR reports the combined market 
share of the desired amount q of the largest firms in a market, which is then divided by the whole 
market size: 
 
𝐶𝑅𝑞𝑡
𝑠 = ∑ 𝑀𝑆𝑖𝑡
𝑠  
𝑞
𝑖=1
 
 
In the equation, q is a number of the largest firms that are included to the sample. Typically, q is set 
to three, four or five. In turn, MS is the market share of a firm i, in industry s, during year t. Market 
share is calculated as before by net sales of a firm. The CR only takes in to account the market share 
of the largest q firms in the industry and ignores the distribution among the other firms, thus giving 
different values than HHI. In addition, problems can arise with CR since it fails to capture the effects 
if there are only a few companies operating in the industry or if there are several firms with small 
market shares. Therefore, using HHI as my primary concentration measure is justified. 
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In this test, I follow Cavalleri, Eliet, McAdam, Petroulakis, Soares, and Vansteenkiste (2019), and 
use q value of four. I use the same double-sorting approach as in sector 3 but replace the HHI-value 
of an industry with CR-value. I exclude the 20% of the smallest stocks to eliminate the small-cap 
stock bias on high R&D-intensity portfolios. Finally, due to data limitations, the sample period is 
from July 2000 to June 2019, but this can be used as a robustness test since this same sample period 
for HHI generates similar values as the period of 1991-2019. 
 
Table 5. Research and development investments -return in competitive and concentrated industries. This table shows 
each portfolio’s monthly raw return and abnormal return (α, in per cents). Stocks that are used, are exchanged in developed 
European countries. The list of countries is based on Kenneth R. French’s data library. Portfolios are sorted on industry 
competition and R&D intensity. Industry competition is measured by concentration ratio (CR). Each firm’s industry is 
determined by the three-digit Standard Industrial Classification (SIC) code. R&D intensity is calculated by dividing R&D 
investment with market equity (RD/ME). All stocks are allocated into three groups based on their CR-values in year t - 
1, using breakpoints for the top 30% (low CR), middle 40% (medium CR) and bottom 30% (high CR). Then, in all groups, 
firms are individually divided into three subgroups based on their RD/ME value in year t – 1 and using breakpoints for 
top 30%, middle 40% and bottom 30%. Monthly returns for formed portfolios are then calculated from July year t to June 
year t + 1 and portfolios are rebalanced after every June. The premium column shows the difference between H-L 
portfolios of Low HHI and High HHI groups. Monthly abnormal returns of portfolios are computed by time-series 
regression of excess returns on factors in Fama and French (1992, 2015) three- and five-factor models and in Carhart 
(1997) four-factor model. I exclude small-cap stocks, which are below 20% based on market value and then use all 
remaining stocks and their equally weighted return. The sample period is from July 1991 to June 2019. The t-statistics 
are noted below monthly abnormal returns in parenthesis. The significance levels for 1%, 5% and 10% are shown by ***, 
** and *, respectively. 
 
 
Table 5 shows corresponding values to Table 3 for Panel B that excludes small-cap firms. The results 
are similar, and it shows the gradual increase in both, high CR and low CR groups. However, the 
premium for R&D-intensive firms is higher among low CR group and this same pattern is seen on 
Table 3 and Panel B. The difference between the two groups is highlighted in the premium column 
in the table. For example, the high-minus-low R&D-intensity portfolio in the low CR group reports 
raw monthly returns of 0.91% with a t-statistic of 4.33. In contrast, the corresponding value for the 
high CR group is 0.61% with a t-statistic of 3.43. The same effect is seen with all three asset-pricing 
models that report higher abnormal returns and t-statistics for R&D-intensive portfolio as well as for 
the high-minus-low R&D-intensity portfolio.  
 
R&D H R&D M R&D L H - L R&D H R&D M R&D L H - L Premium
0.87* 0.65* 0.26 0.61*** 1.08** 0.52 0.17 0.91*** 0.30
(1.94) (1.68) (0.70) (3.43) (2.50) (1.16) (0.39) (4.33) (1.36)
0.09 0.00 -0.38*** 0.48*** 0.39** -0.08 -0.37** 0.76*** 0.29
(0.54) (0.01) (3.01) (2.82) (2.12) (0.40) (2.04) (3.70) (1.36)
0.34** 0.12 -0.22* 0.55*** 0.57*** 0.19 0.12 0.69*** 0.14
(2.02) (0.87) (1.74) (3.18) (3.09) (1.07) (0.67) (3.26) (0.65)
0.26 -0.01 0.31** 0.57*** 0.62*** 0.38** 0.01 0.61*** 0.04
(1.46) (0.06) (2.30) (3.32) (3.22) (2.07) (0.05) (2.94) (0.17)
Raw return
Low competition (High CR) High competition (Low CR)
Fama-French three-factor 
Carhart four-factor
Fama-French five-factor 
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Table 6 reports corresponding values to Table 4 and Panel B. The results show similar returns, even 
though they are slightly lower with smaller t-statistics. The competition premium is higher among the 
high R&D-intensity group than it is for low R&D-intensity group. The difference between the two 
groups is highlighted in the premium column in the table. For example, the raw monthly return for 
low-minus-high CR portfolio in high R&D-intensity group is 0.21% with a t-statistic of 1.33. The 
corresponding value for the low R&D-intensity group is -0.09% with 0.52 t-statistic. The same pattern 
is shown by all three asset-pricing models, even though the Fama-French five-factor model gives a 
larger t-statistic for low-minus-high CR portfolio. 
 
Table 6. Research and development investments -return in competitive and concentrated industries. This table shows 
each portfolio’s monthly raw return and abnormal return (α, in per cents). Stocks that are used, are exchanged in developed 
European countries. The list of countries is based on Kenneth R. French’s data library. Portfolios are sorted on industry 
competition and R&D intensity. Industry competition is measured concentration ratio (CR). Each firm’s industry is 
determined by the three-digit Standard Industrial Classification (SIC) code. R&D intensity is calculated by dividing R&D 
investment with market equity (RD/ME). All stocks are allocated into three groups based on their CR-values in year t - 
1, using breakpoints for the top 30% (low CR), middle 40% (medium CR) and bottom 30% (high CR). Then, in all groups, 
firms are individually divided into three subgroups based on their RD/ME value in year t – 1 and using breakpoints for 
top 30%, middle 40% and bottom 30%. Monthly returns for formed portfolios are then calculated from July year t to June 
year t + 1 and portfolios are rebalanced after every June. The premium column shows the difference between L-H 
portfolios of High R&D and low R&D groups. Monthly abnormal returns of portfolios are computed by time-series 
regression of excess returns on factors in Fama and French (1992, 2015) three- and five-factor models and in Carhart 
(1997) four-factor model. I exclude small-cap stocks, which are below 20% based on market value and then use all 
remaining stocks and their equally weighted return. The sample period is from July 1991 to June 2019. The t-statistics 
are noted below monthly abnormal returns in parenthesis. The significance levels for 1%, 5% and 10% are shown by ***, 
** and *, respectively. 
 
 
I also created portfolios including all stocks and their value-weighted returns. This table shows similar 
results when it comes to the monthly returns. However, concluding the table on this paper is not 
relevant, since the t-statistics on this table are mainly insignificant but it also shows the return 
premium for the high-minus-low R&D-intensity portfolio in the competitive industries group. In 
addition, Hoberg and Phillips (2010) show an alternative Herfindahl-Hirschman Index that considers 
private firms. They show that using both, public and private firms, to calculate the index, does not 
make major changes to the HHI values. Finally, Gu (2016) tests if the financial constraint or 
innovation ability of a firm affects the return premium for firms with high R&D-intensity in 
CR L CR M CR H L - H CR L CR M CR H L - H Premium
0.17 0.43 0.26 -0.09 1.08** 0.95** 0.87* 0.21 0.30
(0.39) (1.06) (0.70) (0.52) (2.50) (2.18) (1.94) (1.33) (1.36)
-0.37** -0.21 -0.38*** 0.01 0.39** 0.25 0.05 0.30** 0.29
(2.04) (1.19) (3.01) (0.08) (2.12) (1.42) (0.54) (1.96) (1.36)
-0.12 0.01 -0.22* 0.10 0.57*** 0.40** 0.34** 0.24 0.14
(0.67) (0.09) (1.74) (0.60) (3.09) (2.19) (2.02) (1.50) (0.65)
-0.01 0.06 -0.31** 0.32** 0.62*** 0.43** 0.26 0.36** 0.04
(0.05) (0.32) (2.30) (2.00) (3.22) (2.29) (1.46) (2.18) (0.17)
Fama-French five-factor 
Low R&D-intensity High R&D-intensity
Raw return
Fama-French three-factor 
Carhart four-factor
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competitive industries. The innovation ability is measured by the average of the coefficient from the 
regression of sales on the previous five-year investments in R&D by following Cohen, Diether and 
Malloy (2013). Financial constraint is based on WW index by Whited and Wu (2006). The outcome 
was that these measures do not affect the results, thus making findings in this paper more robust.  
 
 
6. Conclusion 
 
In this paper, I have examined the joint effect between R&D investments and industry competition 
level on stock returns in developed European countries from 1991 to 2019. The results give new 
perspectives on the positive R&D-return relation as well as on the competition-return relation that 
have been studied quite a lot by researchers. In more competitive industries, firms compete against 
their rivals and frequently enter in innovation races. Since the winner of the race often takes the 
market share for itself, the other companies have to suspend or even abandon their R&D projects. 
This makes the potential future cash flows more uncertain in competitive industries. Thus, R&D-
intensive firms are exposed to more systematic risk, especially in competitive industries. 
 
My findings support these insights and show that the positive return premium between high R&D 
intensity portfolio and low R&D intensity portfolio is larger among competitive industries than in 
concentrated industries. I also find that competition-return relation exists mainly among R&D-
intensive companies. Low R&D intensity companies do not generate higher returns in a more 
competitive environment but R&D-intensive firms show gradually increasing returns when 
competitiveness increases. I have tested the method with an alternative way to calculate the 
competitiveness level of an industry, which reported similar results. I also tested my hypothesis in 
two different ways by first including and then excluding small-cap stocks. I then showed the results 
on three different asset-pricing models to show robustness on my findings. 
 
To conclude, the findings suggest that competition level is a key factor among R&D-intensive firms. 
It affects the firms’ risk and return profiles, and thus explains a significant part of the R&D premium 
that has been discovered in prior studies. This paper leaves the potential to the future to examine why 
the relation between R&D-intensity and industry competition is stronger among the U.S. companies 
and why R&D-intensive firms in Europe generate positive abnormal returns also in concentrated 
industries but in the U.S., they give very small or negative excess returns. 
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